Literature DB >> 1732074

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol.

C M Hunt1, P B Watkins, P Saenger, G M Stave, N Barlascini, C O Watlington, J T Wright, P S Guzelian.   

Abstract

The N-demethylation of erythromycin and 6 beta-hydroxylation of cortisol are both functions of the glucocorticoid-inducible CYP3A in human liver microsomes. To determine whether 6 beta-hydroxylation and erythromycin N-demethylation are catalyzed by similar or distinct CYP3A isoforms, erythromycin N-demethylase activity, as reflected by the recently described 14[C]-erythromycin breath test, was compared with urinary 6 beta-hydroxycortisol/cortisol ratios, a measure of cortisol 6 beta-hydroxylase activity, in nine patients. Erythromycin N-demethylation varied fourfold and 6 beta-hydroxycortisol/cortisol ratios varied sevenfold among the subjects; no correlation was found between these activities (r2 = 0.065). New noninvasive tests of CYP3A strongly suggest cortisol 6 beta-hydroxylation and erythromycin N-demethylation are performed by distinct CYP3A isoforms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732074     DOI: 10.1038/clpt.1992.3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 3.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 4.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 5.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

8.  Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.

Authors:  P K Honig; D C Wortham; K Zamani; D P Conner; J C Mullin; L R Cantilena
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.

Authors:  Ping Huang; Bing Zhu; Lian-Sheng Wang; Dong-Sheng Ouyang; Song-Lin Huang; Xiao-Ping Chen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

10.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.